Prognostic value of indoleamine 2,3 dioxygenase in patients with higher‐risk myelodysplastic syndromes treated with azacytidine

Hypomethylating agents (HMAs) are widely used in patients with higher‐risk myelodysplastic syndromes (MDS) not eligible for stem cell transplantation; however, the response rate is <50%. Reliable predictors of response are still missing, and it is a major challenge to develop new treatment strategies. One current approach is the combination of azacytidine (AZA) with checkpoint inhibitors; however, the potential benefit of targeting the immunomodulator indoleamine‐2,3‐dioxygenase (IDO‐1) has not yet been evaluated. We observed moderate to strong IDO‐1 expression in 37% of patients with high‐risk MDS. IDO‐1 positivity was predictive of treatment failure and shorter overall survival. Moreover, IDO‐1 positivity correlated inversely with the number of infiltrating CD8+ T cells, and IDO‐1+ patients failed to show an increase in CD8+ T cells under AZA treatment. In vitro experiments confirmed tryptophan catabolism and depletion of CD8+ T cells in IDO‐1+ MDS, suggesting that IDO‐1 expression induces an immunosuppressive microenvironment in MDS, thereby leading to treatment failure under AZA treatment. In conclusion, IDO‐1 is expressed in more than one‐third of patients with higher‐risk MDS, and is predictive of treatment failure and shorter overall survival. Therefore, IDO‐1 is emerging as a promising predictor and therapeutic target, especially for combination therapies with HMAs or checkpoint inhibitors.

[1]  Sheng Wei,et al.  A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3‐Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes , 2019, Clinical lymphoma, myeloma & leukemia.

[2]  Linda W. Martin,et al.  Indoleamine-2,3-Dioxygenase in Non–Small Cell Lung Cancer: A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1 , 2018, The American journal of surgical pathology.

[3]  J. Witte,et al.  Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma , 2018, Clinical Cancer Research.

[4]  T. Haferlach,et al.  Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature , 2018, Oncotarget.

[5]  B. Somer,et al.  Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer. , 2018 .

[6]  M. Lim,et al.  Prognostic implications of tumor-infiltrating macrophages, M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxygenase-positive cells in primary diffuse large B-cell lymphoma of the central nervous system , 2018, Oncoimmunology.

[7]  C. Zahnow,et al.  DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer , 2018, Nature Communications.

[8]  Huidong Shi,et al.  A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression , 2017, Scientific Reports.

[9]  Z. Estrov,et al.  Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. , 2017, Blood.

[10]  G. Garcia-Manero,et al.  Decitabine in TP53-Mutated AML. , 2017, The New England journal of medicine.

[11]  Indoximod Combo Triggers Responses in Melanoma. , 2017, Cancer discovery.

[12]  P. Walker,et al.  Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing , 2016, PloS one.

[13]  G. Mufti,et al.  Mutations in histone modulators are associated with prolonged survival during azacitidine therapy , 2015, Oncotarget.

[14]  M. Voso,et al.  Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN. , 2015, Leukemia research.

[15]  F. Gherlinzoni,et al.  Complex karyotype, older age, and reduced first‐line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long‐term follow‐up , 2015, American journal of hematology.

[16]  C. Sheridan.  IDO inhibitors move center stage in immuno-oncology , 2015, Nature Biotechnology.

[17]  D. Neuberg,et al.  TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. , 2014, Blood.

[18]  T. Haferlach,et al.  Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia , 2014, Haematologica.

[19]  C. Preudhomme,et al.  Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. , 2014, Leukemia research.

[20]  Peter A. Jones,et al.  Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers , 2014, Oncotarget.

[21]  S. Parmar,et al.  Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents , 2013, Leukemia.

[22]  A. Jankowska,et al.  Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms , 2014, Leukemia.

[23]  W. J. Ramsey,et al.  A phase I study of indoximod in combination with docetaxel in metastatic solid tumors. , 2013 .

[24]  B. Quesnel,et al.  Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification. , 2013, Leukemia research.

[25]  H. Kantarjian,et al.  Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. , 2012, Blood.

[26]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[27]  C. Steidl,et al.  New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Fisher,et al.  Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial , 2011, Clinical Cancer Research.

[29]  B. Quesnel,et al.  Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias , 2011, Leukemia.

[30]  A. Liston,et al.  Regulatory T Cells , 2011, Methods in Molecular Biology.

[31]  J. Issa,et al.  Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy , 2010, Cancer.

[32]  D. Munn,et al.  Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. , 2009, Blood.

[33]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[34]  W. Hamdi,et al.  Clinical significance of regulatory T cells in patients with myelodysplastic syndrome , 2009, European journal of haematology.

[35]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[36]  M. Bitzer,et al.  Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. , 2008, Blood.

[37]  D. Vignali,et al.  How regulatory T cells work , 2008, Nature Reviews Immunology.

[38]  G. Mufti,et al.  CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). , 2007, Blood.

[39]  R. Widen,et al.  Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome , 2007, Leukemia.

[40]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[41]  U. Grohmann,et al.  The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells1 , 2006, The Journal of Immunology.

[42]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[43]  J. Bourhis,et al.  Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes , 2006, Leukemia.

[44]  Ulrich Göbel,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 20, 2013. For personal use , 2004 .

[45]  U. Grohmann,et al.  Modulation of tryptophan catabolism by regulatory T cells , 2003, Nature Immunology.

[46]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[47]  U. Grohmann,et al.  T cell apoptosis by tryptophan catabolism , 2002, Cell Death and Differentiation.

[48]  F. Garrido,et al.  Rexpression of HLA class I antigens and restoration of antigen‐specific CTL response in melanoma cells following 5‐aza‐2′‐deoxycytidine treatment , 2001, International journal of cancer.

[49]  D. Munn,et al.  Inhibition of  T Cell Proliferation by Macrophage Tryptophan Catabolism , 1999, The Journal of experimental medicine.

[50]  W. Remmele,et al.  [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. , 1987, Der Pathologe.